Does Tufts Health Plan Cover Forteo (Teriparatide)?

What Is Forteo and Why Is It Prescribed?

Forteo (teriparatide) is a recombinant fragment of human parathyroid hormone (PTH 1-34) that stimulates new bone formation rather than simply slowing bone loss. The FDA approved teriparatide in 2002 for postmenopausal women with osteoporosis at high fracture risk, men with primary or hypogonadal osteoporosis, and women and men with glucocorticoid-induced osteoporosis [1]. A subsequent FDA approval in 2019 extended the indication to include premenopausal women with glucocorticoid-induced osteoporosis [1].

How Teriparatide Builds Bone

Unlike antiresorptives such as alendronate, teriparatide works by transiently raising PTH levels, which drives osteoblast activity and net bone formation. In the key Neer et al. Trial (N=1,637), teriparatide 20 mcg/day reduced new vertebral fractures by 65% (relative risk 0.35, 95% CI 0.22 to 0.55, P<0.001) and nonvertebral fragility fractures by 53% compared with placebo over a median 19 months [2]. Lumbar spine BMD increased by 9.7% in the 20-mcg group versus a 0.7% decrease in the placebo group [2].

FDA Labeling Constraints That Drive Coverage Rules

The FDA label carries a black-box warning about osteosarcoma risk observed in rat studies and restricts lifetime use to 24 months [1]. Tufts Health Plan, like most payers, directly encodes this 24-month cap into its prior-authorization criteria. Any request for a third year of therapy will be denied unless the prescriber provides extraordinary clinical justification, which virtually no plan accepts.

Available Formulations

Brand-name Forteo is a prefilled 2.4 mL pen delivering 20 mcg per dose for up to 28 days per pen. Eli Lilly's own authorized generic launched in 2019 at a lower list price, and multiple other generic teriparatide products followed. Tufts formularies may prefer the generic over brand Forteo; confirming which product is covered under your specific plan before dispensing saves time.

How Tufts Health Plan Formularies Work

Tufts Health Plan operates several distinct product lines: commercial/employer plans (Tufts Health Direct, Tufts Health Together), Medicare Advantage plans (Tufts Health Plan Medicare Preferred), and MassHealth/Medicaid managed-care products. Each product line maintains its own formulary, and Forteo's tier placement and prior-authorization rules differ across them.

Commercial Formularies

On most Tufts commercial formularies reviewed as of 2024, teriparatide sits on Tier 4 (specialty preferred) or Tier 5 (specialty non-preferred). Cost-sharing at Tier 4 is typically 20 to 25% coinsurance after deductible; Tier 5 can reach 33% coinsurance. A 28-day supply of brand Forteo carries a list price near $3,200, meaning 25% coinsurance equals roughly $800 per month before manufacturer coupons or assistance programs [3].

Medicare Advantage Formularies

Under Tufts Health Plan Medicare Preferred plans, Forteo falls under Part D drug coverage. Medicare Part D plans cannot use manufacturer coupons toward the out-of-pocket threshold, so list-price coinsurance is the true cost for most Medicare beneficiaries until the catastrophic coverage phase. The Inflation Reduction Act caps Medicare Part D out-of-pocket drug costs at $2,000 per year beginning in 2025 [4], which meaningfully reduces exposure for patients on specialty-tier medications like Forteo.

Medicaid / MassHealth

MassHealth (Massachusetts Medicaid), for which Tufts Health Together is a managed-care option, covers teriparatide with prior authorization aligned with MassHealth drug coverage standards. Cost-sharing for MassHealth members is minimal, but the prior-authorization clinical criteria are still enforced.

Prior Authorization Criteria for Forteo Under Tufts

Prior authorization (PA) is required for Forteo on essentially every Tufts plan variant. The PA criteria are derived from clinical guidelines including the American Association of Clinical Endocrinology (AACE) 2020 Postmenopausal Osteoporosis Guidelines [5] and the Endocrine Society's 2019 Pharmacological Management of Osteoporosis in Postmenopausal Women guideline [6].

Typical Clinical Criteria

To satisfy PA, prescribers generally must document ALL of the following:

• Diagnosis: Confirmed osteoporosis by DXA T-score of -2.5 or below at the lumbar spine, femoral neck, or total hip, OR a low-trauma (fragility) fracture in the past [7].
• High fracture risk: A FRAX 10-year major osteoporotic fracture probability at or above 20%, or hip fracture probability at or above 3%, per the National Osteoporosis Foundation thresholds [8].
• Step therapy: Prior trial and failure, intolerance, or contraindication to at least one oral bisphosphonate (typically alendronate 70 mg weekly for at least 12 months). Some Tufts PA policies require two prior agents.
• Duration limit: Initial approval covers 6 to 12 months; renewal requires documentation of BMD response or continued high fracture risk.
• Lifetime cap: No approval beyond 24 cumulative months, consistent with FDA labeling [1].

What "Failure" of a Bisphosphonate Means to Tufts Reviewers

A documented fragility fracture while adherent to bisphosphonate therapy for at least 12 months generally qualifies as failure. Persistent low BMD (T-score remaining below -2.5) after two or more years of bisphosphonate therapy may also qualify. Intolerance due to GI adverse effects requires physician attestation and ideally documentation that intravenous alternatives (zoledronic acid 5 mg IV annually) were also considered or tried, because Tufts reviewers are trained to ask whether IV bisphosphonate circumvents GI intolerance.

Glucocorticoid-Induced Osteoporosis Criteria

For patients on long-term glucocorticoid therapy (prednisone equivalent of 7.5 mg/day or more for 3 months or longer), the American College of Rheumatology 2022 guideline conditionally recommends anabolic therapy in high-risk patients even without prior bisphosphonate failure [9]. Tufts PA criteria for glucocorticoid-induced osteoporosis may reflect this lower bar; prescribers should cite the ACR guideline explicitly when submitting the PA for this indication.

Step Therapy: Which Drugs Must Be Tried First?

Step therapy for Forteo under Tufts typically runs through the following sequence. Exact requirements vary by plan year and formulary update.

Step 1: Oral Bisphosphonates

Alendronate (generic, $10, $15/month) is the preferred first-line agent in almost every osteoporosis guideline and every payer's step-therapy protocol [5][6]. Risedronate is an acceptable alternative. Ibandronate is listed on some formularies but is not recommended as a hip-fracture risk reducer in AACE 2020 guidance [5], and Tufts reviewers may not accept it as a valid step.

Step 2: IV or Alternative Antiresorptives

If oral bisphosphonates fail or are contraindicated due to renal impairment (eGFR <35 mL/min per 1.73 m² for most oral bisphosphonates [10]), Tufts may require zoledronic acid 5 mg IV annually or denosumab 60 mg subcutaneously every 6 months before approving Forteo. Some plan variants skip this requirement for patients with vertebral fragility fractures, aligning with the AACE 2020 "very high risk" pathway that recommends anabolic-first therapy [5].

Anabolic-First Approach for Very High-Risk Patients

The AACE 2020 guideline states: "For patients at very high fracture risk (e.g., very low T-score <-3.0, multiple prior fractures, fracture while on osteoporosis therapy), anabolic agents are preferred as initial therapy" [5]. Prescribers can use this language directly in the PA narrative to argue that step therapy is clinically inappropriate for a specific patient, which is the most effective mechanism for bypassing the bisphosphonate requirement.

How to Submit a Prior Authorization to Tufts for Forteo

A well-organized PA submission significantly reduces the chance of denial. The following checklist reflects the documentation Tufts reviewers look for.

Required Documentation

1. Current DXA report with T-scores at lumbar spine, femoral neck, and total hip (must be within the past 24 months for most plans).
2. FRAX calculation printout from the WHO FRAX tool showing 10-year fracture probability [8].
3. Prior treatment records showing drug name, dose, duration, and reason for discontinuation or failure (lab values, fracture events, or adverse-effect notes).
4. ICD-10 codes: M81.0 (postmenopausal osteoporosis without fracture), M80.08XA (postmenopausal osteoporosis with vertebral fracture, first encounter), or the appropriate glucocorticoid-induced code (M81.6) as applicable.
5. Letter of medical necessity signed by the treating physician, referencing specific guideline citations.

Timelines

Tufts is subject to Massachusetts General Law requirements for PA decisions. Standard PA decisions must be issued within 3 business days; urgent decisions within 24 hours if the prescriber certifies that delay would seriously jeopardize the patient's health [11].

What to Do If Tufts Denies Coverage for Forteo

Denial is not the end of the road. Tufts, like all Massachusetts-licensed insurers, must follow the Massachusetts External Review Program, which is administered by the Division of Insurance [11].

Internal Appeal

File a written internal appeal within 180 days of the denial notice. Include all documentation listed above plus any new clinical evidence, such as a recent fracture event or a significant drop in BMD since the last DXA. Ask the prescriber to include a peer-to-peer review request; many Tufts medical directors reverse denials during physician-to-physician calls when the prescriber can cite the AACE very-high-risk criteria [5] directly.

External Review

If the internal appeal is denied, request an independent external review through the Massachusetts Division of Insurance. External reviewers are board-certified physicians who apply clinical standards rather than plan formulary criteria. A 2021 analysis of external reviews across Massachusetts commercial plans found that external reviewers overturned insurer denials in approximately 39% of cases involving specialty medications [12].

Expedited Review for Urgent Cases

Patients who are actively fracturing or who have severe vertebral osteoporosis with documented height loss greater than 4 cm should be flagged as urgent. Expedited review must be completed within 72 hours under Massachusetts law [11].

Cost Assistance Programs When Coverage Falls Short

Even with coverage, specialty-tier cost-sharing for Forteo can be prohibitive. Several programs address this.

Lilly Cares Foundation

The Lilly Cares Foundation Patient Assistance Program provides Forteo at no cost to commercially insured patients who meet income criteria (generally household income at or below 400% of the federal poverty level) and to uninsured patients [13]. The application is submitted by the prescriber's office and processed within approximately two weeks.

Lilly Insulin Value Program (Forteo Copay Card)

For commercially insured patients who do not qualify for the full patient assistance program, Eli Lilly offers a copay savings card that may reduce out-of-pocket cost to as low as $25 per month [13]. Medicare and Medicaid patients are not eligible for manufacturer copay cards.

Generic Teriparatide Cost

Generic teriparatide from manufacturers such as Sun Pharmaceutical and Alvogen carries a list price roughly 30 to 40% below brand Forteo. If Tufts places the generic on a lower tier than brand Forteo, switching to the generic is the fastest way to reduce cost-sharing without navigating assistance program paperwork. Ask the prescriber to write "teriparatide" (generic) rather than "Forteo" on the prescription.

Comparing Forteo to Other Anabolic Agents Covered by Tufts

When Forteo is denied or cost-sharing is unacceptable, two other anabolic or dual-action agents may be available.

Tymlos (Abaloparatide)

Abaloparatide 80 mcg subcutaneous daily (Radius Health) received FDA approval in 2017 [14]. In the ACTIVE trial (N=2,463), abaloparatide reduced new vertebral fractures by 86% vs. Placebo (P<0.001) and nonvertebral fractures by 43% (P=0.049) over 18 months [15]. Some Tufts formularies place abaloparatide on a lower specialty tier than brand Forteo, making it a cost-effective alternative. Prior-authorization criteria are similar.

Evenity (Romosozumab)

Romosozumab 210 mg subcutaneous monthly (Amgen/UCB) is a sclerostin inhibitor with both anabolic and antiresorptive properties, approved by the FDA in 2019 [16]. The ARCH trial (N=4,093) showed romosozumab followed by alendronate reduced vertebral fractures by 48% compared with alendronate alone over 24 months [17]. Tufts coverage criteria for romosozumab are similar to Forteo but the drug carries an FDA black-box warning for cardiovascular risk; patients with prior MI or stroke are not candidates [16].

The table below summarizes the three anabolic/dual-action agents across key coverage variables as a practical decision framework for prescribers navigating Tufts formulary choices:

| Agent | FDA Approval | Lifetime Duration | Typical Tufts Tier | Key PA Difference | |---|---|---|---|---| | Teriparatide (Forteo/generic) | 2002 | 24 months | Tier 4 to 5 | Step therapy through bisphosphonate | | Abaloparatide (Tymlos) | 2017 | 24 months | Tier 4 (varies) | Step therapy through bisphosphonate | | Romosozumab (Evenity) | 2019 | 12 months | Tier 4 to 5 | CV exclusion; bisphosphonate step often required |

Monitoring Requirements That Affect Continued Coverage

Tufts renewal PA for Forteo typically requires documented monitoring. Missing labs or DXA results can trigger a renewal denial even when the drug is clearly helping.

BMD Monitoring

Repeat DXA at 12 to 24 months is standard of care per the Endocrine Society 2019 guideline [6]. A response showing less than 3 to 5% increase in lumbar spine BMD does not necessarily justify discontinuation, because teriparatide's main benefit is anti-fracture efficacy independent of BMD change in some patients, but Tufts reviewers may expect to see a BMD trend.

Biochemical Markers

Bone turnover markers such as serum procollagen type 1 N-terminal propeptide (P1NP) can rise 3 to 6-fold within 1 to 3 months of starting teriparatide and are used by some clinicians to confirm anabolic response [18]. Including P1NP values in the renewal PA submission shows Tufts reviewers that the prescriber is actively monitoring response.

Calcium and Vitamin D

Teriparatide transiently raises serum calcium. The FDA label recommends that patients have adequate calcium (1,000 to 1,200 mg/day) and vitamin D (600 to 800 IU/day) intake and that hypercalcemia be excluded before each prescription renewal [1]. Documenting a serum calcium within normal limits at the time of renewal strengthens the PA submission and reduces the chance of a clinical-appropriateness denial.

Sequential Therapy: What Comes After Forteo?

After completing 24 months of teriparatide, the gains in bone density and strength are lost rapidly without follow-on antiresorptive therapy. This is not a gray area.

Evidence for Sequential Antiresorptive Therapy

The DATA-Switch trial (N=94) showed that transitioning from teriparatide to denosumab produced further BMD gains of 6.6% at the spine and 4.0% at the hip over 24 months [19]. Transitioning to alendronate preserves but does not substantially add to teriparatide-induced BMD gains [19]. The Endocrine Society 2019 guideline explicitly states: "After completing a course of teriparatide or abaloparatide, treatment with an antiresorptive agent is recommended to maintain bone density gains" [6].

Coverage for Sequential Therapy

Tufts covers alendronate generically at Tier 1 ($0, $10 copay), making it the lowest-friction follow-on option. Denosumab (Prolia 60 mg subcutaneous every 6 months) requires its own PA under Tufts but is generally approvable as sequential therapy following teriparatide given the DATA-Switch evidence [19]. Prescribers should begin the denosumab PA at month 20 of teriparatide treatment to avoid a gap in therapy.